Crinetics Pharmaceuticals (CRNX) Financials

$84.95

$0.00 (0.00%)

As on 02-Sep-2026 09:30EDT

Market cap

$9,013 Mln

Revenue (TTM)

$42 Mln

P/E Ratio

--

P/B Ratio

7.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	42.16	7.70	1.04	4.01	4.74	1.08
Cost of Revenue	90.36	1.08	2.79	1.10	1.39	1.26
Gross Profit	41.80	6.62	1.04	4.01	4.74	1.08
Operating Expenses	590.89	523.39	339.89	226.62	172.62	108.78
Operating Profit (EBIT)	-549.09	-516.77	-338.85	-222.61	-167.88	-107.70
Other Income	--	--	--	--	--	--
Profit before Tax	-501.43	-465.14	-298.41	-214.53	-163.92	-107.64
Provision for Tax	0.18	0.18	--	0.93	-3.96	-0.92
Profit after Tax (Net Income)	-501.61	-465.32	-298.41	-214.53	-159.95	-106.72
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-163.92	-107.64

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	1,191.96	992.08	1,324.81	539.11	316.33	331.94
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	50.01	58.34	50.10	52.31	8.13	3.08
Current Liabilities	79.92	85.07	59.68	43.94	27.72	16.00
Total Liabilities	1,401.80	1,135.50	1,434.59	635.35	352.18	351.02

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	77.52	87.15	59.20	61.20	6.99	6.30
Current Assets	1,244.36	1,048.34	1,375.39	574.15	345.18	344.72
Total Assets	1,401.80	1,135.50	1,434.59	635.35	352.18	351.02
Total Debt*	47.19	48.54	51.72	51.73	3.08	4.01
Net Current Assets	1,164.45	963.27	1,315.70	530.21	317.46	328.73

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-377.92	-225.97	-166.31	-115.21	-88.59
Cash Flow from Investing Activities	--	173.91	-574.82	-200.41	-173.98	-56.48
Cash from Financing Activities	--	40.61	1,010.44	388.94	121.96	252.68
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-5.06	-4.95	-3.26	-3.19	-2.97	-2.36
Cash EPS ($)	--	-4.91	-3.23	-3.18	-2.95	-2.34
Adjusted Book Value ($)	--	10.55	14.48	8.03	5.88	7.34
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-4.02	-2.47	-2.48	-2.14	-1.96
Free Cash Flow per Share ($)	--	-4.08	-2.51	-2.55	-2.17	-1.97

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-38.50	-30.34	-47.14	-48.81	-41.94
ROE (%)	-45.93	-40.17	-32.02	-50.16	-49.35	-42.61
ROA (%)	-36.35	-36.21	-28.83	-43.45	-45.49	-39.94
EBIT Margin (%)	-1,216.98	-6,043.88	-28,720.69	-5,345.85	-3,544.06	-9,990.91
Net Margin (%)	-1,189.88	-6,046.22	-28,720.69	-5,345.85	-3,376.69	-9,899.72
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	2,928.45	6.41	-0.74	-0.15	3.39	14.18
EBIT Growth (%)	-38.72	-55.87	-39.10	-27.79	-55.88	-43.69
Net Profit Growth (%)	-35.63	-55.93	-39.10	-34.12	-49.88	-46.46
EPS Growth (%)	-23.03	-0.52	-0.02	-0.08	-0.26	-0.07
Book Value Growth (%)	-9.60	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-9.41	-15.68	-11.14	-6.16	-12.04
Price / Book Value	7.56	4.41	3.53	4.43	3.11	3.87
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-13.40	-7.37	-11.42	-8.82	-3.92	-8.95
Close Price ($)	37.42	46.55	51.13	35.58	18.30	28.41
High Price ($)	57.99	53.55	62.53	37.88	28.95	28.82
Low Price ($)	25.83	24.10	33.67	15.23	15.37	13.29
Market Cap ($ Cr)	9,012.79	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.05	0.04	0.10	0.01	0.01
Short term debt to equity ratio	0.01	0.01	0.01	0.01	0.00	0.00
Current Ratio	15.57	12.32	23.04	13.07	12.45	21.55
Quick Ratio	15.53	12.30	23.04	--	--	21.68
Interest Coverage	--	--	--	--	-38.89	-1,765.61

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	28.36	7.69	815.21	233.02	51.19	188.22
Asset Turnover	0.03	0.01	0.00	0.01	0.01	0.00
Receivable days	--	215.04	3,132.40	535.91	171.71	654.27
Inventory Days	--	343.19	--	--	-533.54	-558.87
Payable days	--	4,831.08	813.19	2,233.91	1,466.13	1,122.38
Cash Conversion Cycle	--	-4,272.85	2,319.21	--	-1,827.96	-1,026.98

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.